Intra caesarean loop (device or system ) insertion
contraception
side effect advantages gynecology obestetrics infertility egypt dumiat ras el bar city
LSCS is the most common obstetric procedure but it can be very difficult to manage in cases of previous LSCS, low lying placenta, and PPH. please check out the youtube links to the videos embedded in this PPT.
ADHESIOLYSIS DURING LSCS https://youtu.be/2Hv80v3yu20
BLADDER DISSECTION https://youtu.be/6qsaTJ1yRUY
RECTUS SHEATH ADHESIOLYSIS https://youtu.be/SryJHjuGsME
VECTIS IN FLOATING HEAD DURING LSCS https://youtu.be/3PECperU8Cw
BREECH DELIVERY https://youtu.be/i-LcmTNNVvU
TRANSVERSE LIE WITH IUFD https://youtu.be/hG28uqpkdpU
CONJOINT TWINS https://youtu.be/KLR7D6wkf38
LSCS IN PLACENTA PREVIA https://youtu.be/dNKQwt4KhVY
SYSTEMATIC PELVIC DEVASCULARISATION https://youtu.be/UwSH6V6GBVw
Pprom by dr alka mukherjee dr apurva mukherjee nagpur indiaalka mukherjee
Preterm premature rupture of the membranes (PPROM) is a pregnancy complication. In this condition, the sac (amniotic membrane) surrounding your baby breaks (ruptures) before week 37 of pregnancy. Once the sac breaks, you have an increased risk for infection. You also have a higher chance of having your baby born early.
In most cases of PPROM, the cause is not known.
These things may increase risk:
• Having a preterm birth in a previous pregnancy
• Having an infection in your reproductive system
• Vaginal bleeding during pregnancy
• Smoking during pregnancy
Symptoms can occur a bit differently in each pregnancy. They can include:
• A sudden gush of fluid from your vagina
• Leaking of fluid from your vagina
• A feeling of wetness in your vagina or underwear
Call your healthcare provider right away if you have these symptoms.
The symptoms of this health problem may be similar to symptoms of other conditions. See your healthcare provider for a diagnosis.
Diagnosis
• pH (acid-base) balance testing. The pH balance of amniotic fluid is different from vaginal fluid and urine. Your healthcare provider will put the fluid on a test strip to check the balance.
• Looking at a sample under a microscope. When amniotic fluid is dry, it has a fern-like pattern.
• ultrasound exam. This is done to check the amount of amniotic fluid around baby.
LSCS is the most common obstetric procedure but it can be very difficult to manage in cases of previous LSCS, low lying placenta, and PPH. please check out the youtube links to the videos embedded in this PPT.
ADHESIOLYSIS DURING LSCS https://youtu.be/2Hv80v3yu20
BLADDER DISSECTION https://youtu.be/6qsaTJ1yRUY
RECTUS SHEATH ADHESIOLYSIS https://youtu.be/SryJHjuGsME
VECTIS IN FLOATING HEAD DURING LSCS https://youtu.be/3PECperU8Cw
BREECH DELIVERY https://youtu.be/i-LcmTNNVvU
TRANSVERSE LIE WITH IUFD https://youtu.be/hG28uqpkdpU
CONJOINT TWINS https://youtu.be/KLR7D6wkf38
LSCS IN PLACENTA PREVIA https://youtu.be/dNKQwt4KhVY
SYSTEMATIC PELVIC DEVASCULARISATION https://youtu.be/UwSH6V6GBVw
Pprom by dr alka mukherjee dr apurva mukherjee nagpur indiaalka mukherjee
Preterm premature rupture of the membranes (PPROM) is a pregnancy complication. In this condition, the sac (amniotic membrane) surrounding your baby breaks (ruptures) before week 37 of pregnancy. Once the sac breaks, you have an increased risk for infection. You also have a higher chance of having your baby born early.
In most cases of PPROM, the cause is not known.
These things may increase risk:
• Having a preterm birth in a previous pregnancy
• Having an infection in your reproductive system
• Vaginal bleeding during pregnancy
• Smoking during pregnancy
Symptoms can occur a bit differently in each pregnancy. They can include:
• A sudden gush of fluid from your vagina
• Leaking of fluid from your vagina
• A feeling of wetness in your vagina or underwear
Call your healthcare provider right away if you have these symptoms.
The symptoms of this health problem may be similar to symptoms of other conditions. See your healthcare provider for a diagnosis.
Diagnosis
• pH (acid-base) balance testing. The pH balance of amniotic fluid is different from vaginal fluid and urine. Your healthcare provider will put the fluid on a test strip to check the balance.
• Looking at a sample under a microscope. When amniotic fluid is dry, it has a fern-like pattern.
• ultrasound exam. This is done to check the amount of amniotic fluid around baby.
A forceps delivery is a type of assisted delivery. Instrumental delivery refers to any delivery process which is assisted by vaginal operations. It is an art, which should be learnt by all obstetricians for optimum maternal and perinatal outcome.
A forceps delivery is a type of assisted delivery. Instrumental delivery refers to any delivery process which is assisted by vaginal operations. It is an art, which should be learnt by all obstetricians for optimum maternal and perinatal outcome.
जादू है उनकी हर एक बात मैं, याद बहुत आती है दिन और रात मैं , कल जब देखा था सपना मैने रात मैं, तब भी उनका ही हाथ था मेरा हाथ मैं .
- via bkb.ai/shayari
दिखावे की मोहब्बत तो जमाने को हैं हमसे पर,
ये दिल तो वहाँ बिकेगा जहाँ ज़ज्बातो की कदर होगी।
- via bkb.ai/shayari
कम से कम अपने बाल तो बाँध लिया करो ।
कमबख्त..
बेवजह मौसम बदल दिया करते हैं ।
- via bkb.ai/shayari
Jab Koi Khayal Dil Se Takrata Hai,Dil Na Chahkar Bhi Khamosh Rah Jata Hai,Koi Sab Kuchh Kahkar Pyar Jatata Hai,Koi Kuchh Na Kahkar Bhi Sab Bool Jata Hai.
- via bkb.ai/shayari
An intrauterine device, also known as intrauterine contraceptive device or coil, is a small, often T-shaped birth control device that is inserted into the uterus to prevent pregnancy. IUDs are one form of long-acting reversible birth control.
The device which is used in the intrauterine drug delivery system is known as an Intrauterine device (IUD) (2). IUDs or intrauterine devices are small artificial objects or devices inserted into the uterus to prevent the occurrence of pregnancy by disrupting the fertilization process as a result of sexual intercourse. They have gained popularity in recent times and are one of the most effective methods of birth control in terms of long-term contraception. It can be easily installed and is flexible. These devices are usually small in size and inserted through the cervix. IUDs reduce the need for abortion with unwanted pregnancies by preventing the effective movement of eggs and sperm. However, it cannot confirm the spread of STIs or STDs such as HIV, gonorrhoea, etc
Topics covered
Introduction
Advantages
Disadvantages
Development of intra uterine devices (IUDs)
Applications
References
learn about various methods of contraception , how to use various contraceptive devices and also learn about the hormonal and emergency contraceptives' methods. here is the detail of post coital methods to prevent pregnancy and terminal methods for sterilization.
Intra -Uterine Device Contraception in KenyaSteven Akach
This is a presentation on the available methods of intrauterine device contraception. Presentation was made by Lorraine Chepng'eno and Steven Akach, both final year medical students at MOI UNIVERSITY SCHOOL OF MEDICINE
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
2. What is an ( IUCD or IUCS ) ?
• It is a small, flexible, plastic device that contains
• Either metal e.g. copper (IUCD = intrauterine contraceptive device)
or
• Hormones e.g. progesterone (IUCS= intrauterine contraceptive system)
and
• Is inserted into the uterus
• To prevent pregnancy.
3. •Intrauterine contraception is highly effective,
very safe, and generally well tolerated by most
women.
•As such, it has become an increasingly popular
method of contraception.
•Despite the overall excellent safety profile, side
effects and complications can occur at the time
of insertion and at different time points
following insertion.
4. the first use of IUDs to caravan drivers who allegedly used intrauterine stones to prevent pregnancies in their camels during long journeys I
n the early 1800s from the stem pessary. This cup-shaped device had a stem that fit into the cervical canal and was designed to be placed in the vagina to support the uterus
n 1902 Hallwig designed a version with a stem that extended into the uterine cavity.
The first published paper on actual IUD insertions was made by Dr. Richard Richter in 1909 in Germany.
The device he inserted was a ring made of silkworm gut, with 2ends of nickel and bronze wire which protruded from the cervical os enabling him both to check the device and remove it.
Shortly after Karl Pust recommended a silkworm ring placed in the uterus with a stiff cervical extension of a tightly wound silk thread and a glass button to cover the cervix.
in the mid 1920s, Ernest Graefenberg the silkworm gut with a coiled metal ring made of an alloy of copper, nickel, and zinc.
Pure silver rings had to be abandoned because silver was absorbed and led to gingival argyrosis of the gums, analogous to the lead line
Dr. Halton used silkworm gut. She wound it around her finger, pressed the ring into a gelatine capsule and pushed the capsule into the uterine cavity, where the gelatine liquefied and the thread
spread out. with and without a beaded tail
in 1930, Gräfenberg using rings made of coiled silver and gold, and then steel. Although the Graefenberg ring was widely used, it was considered a risky method in continental Europe and in the
U.S.
In 1934 in Japan, Ota modified this design slightly by adding a supportive structure to the ring (the center of his gold or silver plated ring).
As late as 1959, Dr. Alan Guttmacher co-authored a paper in which the IUD was condemned for its ineffectiveness, potential source of infection, and its carcinogenic potential.
Since 1960, various kinds of IUDs were made of plastic (polyethylene) impregnated with barium sulfate so that they would be visible on an x-ray.
the coil in January I962. Dr. J. Lippes The next year brought the Birnberg "BOW" and the double coil, the so-called safety-coil. The devices were widely distributed
After that the Maizlin spring, the Incon ring, the Antigon, the "M" device, the LEM, the Dalkon Shield, and more than a dozen others.
in the 1960s and 1970s with the introduction of such models as the Margulies Spiral, the Lippes Loop, the Saf-T-Coil, the Birnberg bow, and the Dalkon Shield
From 1985 to 1988, by the Alza Corporation only the Progestasert IUD In 1976 was available in the United States
the copper-containing by Jaime Zipper of Chile The Cu-7 with a copper wound stem was developed in 1971 ParaGard IUD, introduced in 1988, contains 300 mm2 of copper on the vertical arm
and 40 mm2 on each of the horizontal arms, the Nova T, and the Multiload-375
for a total of 380 mm levonorgestrel-containing Mirena IUD in 2001
modern generation of IUDs in China includes a stainless steel ring with copper wire that also releases indomethacin (very effective with a low expulsion rate and less blood loss), a V-shaped
copper IUD, and a copper IUD shaped like the uterine cavity.
Future IUDs Modifications of the copper IUD are being studied throughout the world. The Ombrelle-250 and Ombrelle-380, designed to be more flexible in order to reduce expulsion and side
effects, have been marketed in France. A frameless IUD, the FlexiGard (also known as the Cu-Fix or the GyneFix),
IUCD History
5. Intrauterine Device Or System Classification
nonmedicated first generation Eg: Lippes loop
• IUCD or IUCS medicated second generation Eg: Copper IUCD
third generation Eg:Hormonal IUCS
7. A fair number of women undergoing caesarean section are
good candidates for using the IUCD for contraception.
It offers the obstetrician an opportunity to insert the IUCD
into the uterus under vision,
thus obviating the fear of perforating the uterus during the
procedure.
A number of women fail to return for availing contraceptive
services, once they leave hospital.
IUCD insertion also offers women a chance to avail this
method of contraception at the same time as they have
caesarean section
8.
9. Advantages
• Inserting an IUD at the time of CS is
• a very attractive option.
• It adds very little time and
• very little cost to the procedure.
• The patient does not have to come back especially for follow-up
• There is no risk of primary perforation as it is performed under direct
vision (secondary perforation is possible).
• When it remain in place a 5-year follow-up seems to indicate that it
will behave similarly to interval insertion in woman with and without
CS.
10. Complications Of IUCD
• Bleeding
• Pain
• Embedment Partial penetration or embedment of ParaGard® in the myometrium can make removal difficult. In some
cases, surgical removal may be necessary.
• Perforation
• Migeration IUD might become embedded in the wall of the uterus or slowly migrate completely through the uterine wall. If this happens, the device
could possibly damage nearby internal organs.
• Expulsion (partial , complete )
• Pregnancy (intrauterine,extrauterine)
• Infection (upper GTI, lower GTI )
• Missed threads ( threads torn, threads retracted in cervical canal or in the uterus , embedded , perforation ,migeration ,
expulsion )
• Malposition and displacement of IUCD
• Infertility
• Wilson’s Disease Theoretically, ParaGard® can exacerbate Wilson’s disease, a rare genetic disease
affecting copper excretion.
11. Two Early Problems With PPIUDCS
• The first problem is Initial expulsion rates,
• although not as high as those after vaginal birth post-partum
insertion, are still unacceptably high (5%–10%). This is the only time
an IUD is inserted into the uterine cavity under direct vision, and the
use of the correct anchor with suturing into the uterine muscle
techniques, and additional training for those inserting the devices.has
the ability to make the expulsion rate close to zero.
• The second problem of importance is missing threads.
• In many GS situations ultrasound is often not available
• their presence in the vagina exist, but often necessitate trimming and
so may require an extra post-partum follow-up.
12. Decrease Expulsion Rate
• With the appropriate technique,
• IUDs inserted immediately after placental delivery or Cesarean section can
be safe and effective.
• Expulsion rates for postpartum insertion vary greatly depending on both
the IUD type and provider’s technique.
• Current information indicates that the expulsion rates may be higher from
10 minutes to 48 hours after delivery than in the first 10 minute period.
• To minimize risk of expulsion, only properly trained providers (according to
relevant national or institutional standards) should insert IUDs postpartum.
• Use of an inserter for IUD placement tends to reduce expulsion risk.
• Clients should be counseled that expulsion rates are higher postpartum
than for interval insertion and should be carefully trained to detect
expulsions.
13. When can an IUD be inserted postpartum?
• An IUD may be inserted:
Immediate Postpartum:
o Postplacental: Insertion within 10 minutes after expulsion of the placenta following a vaginal delivery on the
same delivery table.
o Intracesarean: Insertion that takes place during a cesarean delivery,
after removal of the placenta and before closure of the uterine incision. Or
immediately after a Cesarean section (special training required)
Within 48 hours after delivery: Insertion within 48 hours of delivery and prior to discharge from the
postpartum ward.
Postabortion: Insertion following an abortion, if there is no infection, bleeding or any other
contraindications.
Extended Postpartum/Interval: )
o As early as four- to six-weeks postpartum, to accommodate women who come to the clinic for routine
postpartum care and who request an IUD. Copper T IUDs may be safely inserted at this time.
o For other types of IUDs, it may be prudent to wait until six-weeks postpartum.
o While women continue to breastfeed.
14. Duration Of Action
• All copper IUCDs are licensed for at least 5 years of use and some are
recommended for longer use.
• The TCu380A is effective for up to 12 years of use and licensed for 10
years.
• In the UK it is widely accepted that if a copper-containing IUCD is
inserted when a woman is 40 years or over it can be retained and will
remain effective until the menopause is confirmed.[
15. The first study on the use of PPIUDCS was by Zerzavy in 1967
• He inserted a Birnberg Bow
• size 5 or 7 and
• sutured it in place at CS.
• After that there were relatively few studies over
many years.
• Sporadic attempts to revive the procedure were
made in the 1970s and 1980s.
• This anxiety regarding PPIUDCS began to
dissipate in the 1990s due to the realization that
the IUD is not primarily responsible for causing
infection
16. Inclusion criteria
• 1. any age; adolescents may receive post-placental IUD insertion
• 2. desiring Paragard or Mirena IUD
• 3. anticipated vaginal (including vaginal birth after cesarean) or
cesarean delivery
• 4. any language for which adequate translation can be obtained
17. Exclusion criteria
• 1. history of sexually transmitted infection during the index pregnancy
• 2. recent (within the last 3 months) or active intrauterine infection
• 3. known abnormal uterine cavity
• 4. standard absolute contraindications (eg: Wilson’s disease, no
Paragard)
18. After enrollment
• subjects should be excluded if:
• 1. Intrapartum fever greater than 38.0 degrees
• 2. Postpartum hemorrhage (greater than 500 ml blood loss for vaginal
deliveries; 1,200cc for cesarean deliveries)
• 3. Rupture of membranes for greater than 24 hours prior to delivery
• 4. Retained placenta requiring manual removal or D&C
19. Insertion In Relation To Uterine Closure
After removal of the placenta
= before closure of the uterine wound
or
= during closure of the uterine wound
(half closure or
two third closure),
the device was inserted
20. Methods Of Insertions
• With threads (Hang up technique)
- From ouside
- From inside
- from inside frameless loop
. With knotted loop of 2-0 chromic catgut suture
• Without threads
frameless loop
- Anchor method
copper T 380 , Multiload or Mirena
-Manually
- Assisted by ring forceps
- IUCD applicator
+ or - Immediate Post-placental Anchoring of TCu380 by Two strands of catgut
were knotted on both transverse arms of the T
21. Hang up technique from outside
Straight needles and surgical thread (chromic catgut or PGA) are
used.
Needle is inserted perpendicularly from the outside to penetrate
the median of the fundus wall to get into the uterine cavity.
Once the surgical thread entered the uterine cavity, the needle is
clamped with rings forceps and pulled out through the lower
uterine segment incision.
Subsequently, an anchor knot is made on the cross-ing arm so that
the IUD is balanced and hanging flexibly on the wall of the fundus.
The IUD string is then cut in the middle of the long thread. Using
ring forceps for clamping the IUD,
it is inserted into the uterine cavity while simultaneously pulling the
surgical thread out of the uterus so that the IUDs
horizontal arm is attached to the middle uterine fundus wall.
The position of IUD remains suspended by the thread.
Then, a knot is made on the outer surface of the uterus so the IUD
will be fixed and hangs from the fundus
22. Hang up technique from Inside
After delivering the fetus and removing the Placenta the
uterus is delivered out from The abdomen through the
laparotomy wound.
A '0' chromic catgut strand is tied at the junction of
the vertical and The curved limbs of the Multiload Cu 375
by a single knot, The straight round body needle is employed
to take one end of this catgut through the wall of the Uterine
fundus At its centre, from inside out
The position of IUD remains suspended by the thread.
Then, a knot is made on the outer surface of the uterus so the
IUD will be fixed and hangs from the fundus
23. GyneFix Postpartum With Cone-Shaped Anchor
the technique consists of the precise placement of the anchoring knot
immediately below the serosa of the uterus, followed by fixing the
knot in place with an absorbable suture.
24. Insertion of Copper T with knotted loop of 2-0 chromic catgut suture
knotted loop of 2-0 chromic catgut suture around the top
of the vertical arm, which is inserted approximately 1
cm into the fundal myometrium
A special inserter had to be designed for the T 380 Postpartum
IUD.
The inserter was equipped with a plastic V-tipped rod
that was controlled manually, permitting the clinician
to determine accurately the depth of the insertion into
the uterine wall.
The rod delivered the knotted loop of 2-0 chromic catgut into
the uterine wall to a depth of no more than 1 cm
When the insertion was completed, the transverse arms of the
T were flush with the endometrial surface at the top of the
Fundal cavity.
After insertion, the catgut dissolved over the next
4 to 6 weeks, leaving the IUD free in the endometrial cavity.
By this time the uterus had involuted to its normal
prepregnancy shape and size.
25. Immediate Post-placental Anchoring of
Frameless IUD
below the polypropylene anchoring knot, a cone-shaped biodegradable
body (polycaprolactone), 4x4 mm in size, is added to retain the device
in the muscular tissue of the uterine fundus
The technique consists of the precise placement of the anchoring knot
immediately below the serosa of the uterine fundus
26. Manual Insertion Of PPIUCD
• Holds the IUCD between the index and middle fingers
of the hand,
• Passes it through the uterine incision and places it at
the uterine fundus;
• Slowly withdraws the hand, ensuring that the IUCD
remains properly placed; and
• If the cervix is closed, dilate
• Closes the uterine incision,
• Taking special care not to incorporate the IUCD
strings into the suture.
27. Assisted By Ring Forceps
• After removal of placenta and membranes,
• uterine cavity was cleaned with sterile gauze
• Copper T 380A was introduced through uterine incision with the
help of long sponge holding forceps (Mirena strings may need to
be trimmed prior to placement).
• It was placed high at the uterine fundus using non touch
technique
• If the cervix is closed, dilate
• Strings were folded upwards pointing towards the fundus to
avoid their inclusion into the suture and it minimizes any chance
of spontaneous expulsion .
• Closure of uterus
28. IUD insertion by the applicator
• The IUD should be placed in the applicator no earlier than 5 minutes before placing
1. Open the package partly in place where the OPEN sign is.
2. Insert the applicator rod - tube until almost touching the bottom / end of the
insert T.
3. Remove the bag and hold the ends of the horizontal arms, insert your thumb and
index fingers. With your other hand, push the applicator so that the touch pad. Then
place the arms deposited in the applicator pad only as far as necessary, to shoulder
pads were made.
4. Please check the position of the ring very low on the enclosed sheet to point to
the depth of the uterus. Now insert is ready to set up.
• . Gently insert the applicator (the rod tube) through the uterine incision , when the
movable contacts the bottom of the upper part of the uterus.
3. Holding the rod in position to slide the applicator tube so as to free the spiral arms
4. Gently push the applicator tube to the front in the direction of the uterus, until a
light resistance occurs. This ensures that the pad is close to the bottom of the uterus.
5. Remove the applicator: - First remove the tube while holding the rod in position,
then gently pull the tube rotation
• If the cervix is closed, dilate
• Strings were folded upwards pointing towards the fundus to avoid their inclusion into
the suture and it minimizes any chance of spontaneous expulsion .
• Closure of uterus
29. Immediate Post-placental Anchoring
of TCu380
Delta-TCu380 postpartum IUD.
Two strands of catgut were knotted on both transverse arms of the T
in an attempt to provide better retention of the iUD in the uterine
cavity.
When the insertion was completed,
the transverse arms of the T were flush with the endometrial surface
at the top of the fundal cavity.
After insertion, the catgut dissolved over the next 4 to 6 weeks,
leaving the IUD free in the endometrial cavity.
By this time the uterus had involuted to its normal prepregnancy
shape and size.
30. Threads = To cut or not to cut
during caesarean section, after delivery of
the baby, placenta and membranes, IUCD was inserted
through the incision in the uterus and the shortened
thread pushed through the cervix from inside the uterus.
Or pushed high in uterine cavity
The IUCD was not anchored to the uterus.
Paragard strings are 12 cm and should not be visualized after insertion;
if the strings are visible, the IUD may be too low and reinserted should be
considered. The strings usually descend spontaneously through the cervix and can
be trimmed at a follow-up visit.
If fundal placement is confirmed and strings are seen, trim to the level of the
cervix.
Mirena strings should also be trimmed to the level of the cervix.
31. Early Complications
• IUD insertion did not significantly increase postoperative pain,
hospital stay, the volume or duration of bleeding, or frequency of
infection.
• The results suggest that IUD insertion during cesarean is a safe and
effective method of fertility control for patients at high reproductive
risk.
32. Late Complications
• Retention rate of PPIUCD was high.
• Spontaneous expulsion in intra-caesarian IUCD was less as fundal placement was
assured at the time of insertion.
• Bleeding problems were the major complaint and the main reason for removal
of PPIUCD
• Results
• Retention rate was 86.33%.
• Spontaneous expulsion was 8.54.
• Bleeding was the main symptom perceived by 88.71% women
• followed by long thread 26.02% and
• pain in lower abdomen 15.90%.
• Total 61.29% women were satisfied and were continuing the method.
33. Bleeding Problems
• Proper insertion (to avoid Malposition and displacement ), custom
fitting to avoid dimensional incompatibilities, or changes in the size,
material, or shape of the IUD have failed to significantly improve IUD-
associated bleeding problems.
• The addition of copper to inert devices appears to slightly improve
bleeding by reducing antifibrinolytic activity,
• although the improvement may be related more to reductions in the
size of the device
• Hormone-releasing devices significantly reduce the amount of
bleeding, but a post-insertion phase of irregular spotting often
occurs.
34. How Can an IUD Cause an Infection?
• IUDs don’t directly cause infections.
• If woman have an existing infection, inserting the IUD may spread it.
• Two common sexually transmitted diseases (STDs) are chlamydia and gonorrhea.
• That’s why some doctors may want to test for STDs before inserting an IUD.
• slightly higher risk of pelvic inflammatory disease (PID) for a few weeks after IUD
is inserted.
• The vagina normally contains some bacteria. If bacteria are pushed up into the
reproductive organs during IUD insertion, it may result in PID.
• May expose client to infection during insertion if infection prevention practices
are not followed (this is minimal with good infection prevention procedures).
35. Conclusion
• PPIUDCS has many practical advantages.
• The recipient can leave with the IUD in place and will be protected from pregnancy even
if she does not attend follow-up, provided the IUD remains in place.
• Further evidence from systematic review of recent studies is providing us with new
information to help make this a more acceptable option for women in the GS and
elsewhere.
• In order to expand access to this procedure there are three main problems to be solved,
namely:
• 1) prevent expulsion – whether by device design or suture technique and provider’s
technique(manual , with ring forceps or with applicator;
• 2) ensure that strings are visible, and if possible do not require adjustment; and
• 3) reduce puerperal bleeding – hopefully by the use of cheaper hormone releasing
devices, which should soon become available.
• it can be concluded that, the quality of evidence was moderate and trials of adequate
power are needed to estimate expulsion rates and side effects.
• The benefit of effective contraception immediately after delivery May outweigh the
disadvantage of increased risk for expulsion